Metrika

  • citati u SCIndeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:6
  • preuzimanja u poslednjih 30 dana:4

Sadržaj

članak: 8 od 34  
Back povratak na rezultate
2018, vol. 52, br. 4, str. 1683-1695
Generičke zabrane novih psihoaktivnih supstanci
Kriminalističko-policijski univerzitet, Beograd

e-adresaradosav.risimovic@kpu.edu.rs
Projekat:
Razvoj institucionalnih kapaciteta, standarda i procedura za suprotstavljanje organizovanom kriminalu i terorizmu u uslovima međunarodnih integracija (MPNTR - 179045)

Ključne reči: nove psihoaktivne supstance; generičke zabrane; 'Spais'; kanabinoidi
Sažetak
Nove psihoaktivne supstance više od deset godina privlače pažnju istraživača. Njihova pojava i sve veća zastupljenost na tržištu droga zahtevaju adekvatnu reakciju svih nadležnih državnih organa. Poseban problem je pravno regulisanje novih droga, koje će u radu biti detaljno obrazloženo. U uvodnom izlaganju ćemo razmatrati pojam NPS, rizike za zdravlje i razloge popularnosti NPS kod korisnika droga. Deo rada se odnosi na alternativne načine regulisanja NPS. Posebna pažnja će biti posvećena generičkim zabranama NPS. Pokušaćemo da odgovorimo na pitanje koje su prednosti i nedostaci generičkog koncepta zabrane novih droga.
Reference
*** (2009) Zakon o bezbednosti hrane. Sl. glasnik RS, br. 41
*** (2005-2016) Krivični zakonik. Sl. glasnik RS, br. 85/2005, 88/2005 - ispr., 107/2005 - ispr., 72/2009, 111/2009, 121/2012, 104/2013, 108/2014 i 94/2016
*** (2010) Zakon o psihoaktivnim kontrolisanim supstancma. Sl. glasnik RS, br. 99
*** (2005-2016) Krivični zakonik. Sl. glasnik RS, br. 85/2005, 88/2005 - ispr., 107/2005 - ispr., 72/2009, 111/2009, 121/2012, 104/2013, 108/2014 i 94/2016
Auwarter, V., i dr. (2009) 832.19 EMCDDA: Early-warning system: Understanding the ‘Spice' phenomenon. 19
Auwärter, V., Dresen, S., Weinmann, W., Müller, M., Pütz, M., Ferreirós, N. (2009) ‘Spice’ and other herbal blends: harmless incense or cannabinoid designer drugs?. Journal of Mass Spectrometry, 44(5): 832-837
Brandt, S.D., King, L.A., Evans-Brown, M. (2014) The new drug phenomenon. Drug Testing and Analysis, 6(7-8): 587-597
Carhart-Harris, R.L., Bolstridge, M., Rucker, J., Day, C.M.J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J.A., Forbes, B., Feilding, A., Taylor, D., Pilling, S., Curran, V.H., Nutt, D.J. (2016) Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry, 3(7): 619-627
Chatwin, C. (2017) Assessing the ‘added value’ of European policy on new psychoactive substances. International Journal of Drug Policy, 40: 111-116
Griffiths, P., Evans-Brown, M., Sedefov, R. (2013) Getting up to speed with the public health and regulatory challenges posed by new psychoactive substances in the information age. Addiction, 108(10): 1700-1703
Hughes, B., Blidaru, T. (2009) Legal responses to new psychoactive substances in Europe. EMCDDA, 6-7
Hughes, B., Winstock, A.R. (2012) Controlling new drugs under marketing regulations. Addiction, 107(11): 1894-1899
Karila, L., Benyamina, A., Blecha, L., Cottencin, O., Billieux, J. (2017) The Synthetic Cannabinoids Phenomenon. Current Pharmaceutical Design, 22(42): 6420-6425
Kikura-Hanajiri, R. (2016) New Designer Drugs in Japan. u: Neuropathology of Drug Addictions and Substance Misuse, Elsevier BV, 1055-1065
Mirkov, Ž.D. (2017) Suočenje okrivljenog u krivičnom postupku - prikaz slučajeva iz prakse pojedinih sudova. Zbornik radova Pravnog fakulteta, Novi Sad, vol. 51, br. 2, str. 433-448
Piggee, C. (2009) Investigating a not-so-natural high. Analytical Chemistry, 81(9): 3205-3207
Reuter, P., Pardo, B. (2017) New psychoactive substances: Are there any good options for regulating new psychoactive substances?. International Journal of Drug Policy, 40: 117-122
Schier, A.R.de M., Ribeiro, N.P.de O., e Silva, A.C.de O., Hallak, J.E.C., Crippa, J.A.S., Nardi, A.E., Zuardi, A.W. (2012) Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug. Revista Brasileira de Psiquiatria, 34: S104-S117
Seddon, T. (2014) Drug policy and global regulatory capitalism: The case of new psychoactive substances (NPS). International Journal of Drug Policy, 25(5): 1019-1024
Simović, M.N., Simović, V.M. (2014) Pojam i značenje načela legaliteta u krivičnom pravu. u: <Čokić Mirela> [ur.] Zbornik radova: Javni i privatni aspekti nužnih pravnih reformi u BiH: Koliko daleko možemo ići?, Tuzla, 27
Stajić, L.S. (2017) Odgovor države na nasilje u porodici. Zbornik radova Pravnog fakulteta, Novi Sad, vol. 51, br. 3-1, str. 657-673
Stojanović, Z. (2011) Krivično pravo - opšti deo. Beograd, 21
Sun, Y., Bennett, A. (2007) Cannabinoids: A New Group of Agonists of PPARs. PPAR Research, 2007: 1-7
van Amsterdam, J., Nutt, D., van den Brink, W. (2013) Generic legislation of new psychoactive drugs. Journal of Psychopharmacology, 27(3): 317-324
van Hout, M.C., Bingham, T. (2013) ‘Silk Road’, the virtual drug marketplace: A single case study of user experiences. International Journal of Drug Policy, 24(5): 385-391
Vardakou, I., Pistos, C., Spiliopoulou, Ch. (2010) Spice drugs as a new trend: Mode of action, identification and legislation. Toxicology Letters, 197(3): 157-162
Waldo, Z.A., Alexandre, S. C.J., E.C. Hallak, J., Bhattacharyya, S., Atakan, Z., Martin-Santos, R., K. McGuire, P., Silveira, G.F. (2012) A Critical Review of the Antipsychotic Effects of Cannabidiol: 30 Years of a Translational Investigation. Current Pharmaceutical Design, 18(32): 5131-5140
Winstock, A.R., Ramsey, J.D. (2010) Legal highs and the challenges for policy makers. Addiction, 105(10): 1685-1687
Zack, M., Poulos, C. (2009) Effects of the atypical stimulant modafinil on a brief gambling episode in pathological gamblers with high vs. low impulsivity. Journal of Psychopharmacology, 23(6): 660-671
 

O članku

jezik rada: srpski
vrsta rada: izvorni naučni članak
DOI: 10.5937/zrpfns52-20362
objavljen u SCIndeksu: 24.05.2019.
metod recenzije: dvostruko anoniman
Creative Commons License 4.0

Povezani članci